It’s really hard to grasp the magnitude of the Sinaptica opportunity. It’s ridiculously huge in scale compared to Nexstim’s current business. We just have to keep our fingers crossed that they get FDA approval, then the path will be wide open for both Nexstim and Sinaptica.
- Over 55 million people worldwide are living with dementia, with numbers expected to triple by 2050 due to aging populations.
- Nearly 10 million new cases of dementia are diagnosed each year.
- Age-Related Risk – Dementia primarily affects older adults, with prevalence increasing significantly after 65 years of age.
- Alzheimer’s disease is the most common type of dementia, accounting for 60-80% of cases.
- Women are at a higher risk than men, likely due to longer life expectancy and hormonal factors.
- High-income countries have higher reported prevalence, but cases are rising rapidly in low- and middle-income countries (LMICs) due to aging populations and limited healthcare access.
- Family history, cardiovascular diseases, diabetes, and unhealthy lifestyles (smoking, poor diet, lack of exercise) contribute to dementia risk.
- Dementia-related costs are projected to exceed $1.3 trillion annually, placing a heavy burden on healthcare systems and caregivers.
- Mortality Rate – Dementia is a leading cause of death, ranking among the top five causes of mortality in many developed nations.
- Though rare, dementia can occur before 65 years of age, accounting for about 5-10% of all cases.